Nouvelle déclaration d'incident
No de la demande: 2011-5535
Numéro de référence du titulaire d'homologation: 4665240
Nom du titulaire (nom légal complet, aucune abbréviation): Sure-Gro Inc.
Adresse: 150 Savannah Oaks Dr.
Ville: Brantford
État: Ontario
Pays: Canada
Code postal /Zip: N3V 1E7
Incident chez un animal domestique
Pays: CANADA
État: MANITOBA
ARLA No d'homologation 26923 ARLA No de la demande d'homologation EPA No d'homologation.
Nom du produit: Wilson AntOut Ant Killer Dust
Oui
Inconnu
Site: Unknown / Inconnu
Inconnu
Propriétaire de l'animal
Dog / Chien
Labrador Retriever
1
Homme
5
140
lbs
Orale
Unknown / Inconnu
>24 hrs <=3 days / >24 h <=3 jours
Système
>24 hrs <=3 days / >24 h <=3 jours
Non
Non
Fully Recovered / Complètement rétabli
Accidental ingestion/Ingestion accident.
(p.ex. description des symptômes tels que la fréquence et la gravité
Caller indicated that owner placed this dust about 2 days ago. Yesterday, the owner noticed her pet having loose stools and diarrhea. The dog is having diarrhea today as well. The caller was advised that because the amount was poorly consistent, the patient was considered to be at low risk of developing clinical signs. If signs develop, there is low risk that those signs will be life-threatening. Dogs tolerate this type of preparation very well, rarely see signs that might indicate cholinesterase inhibition. Until about 20 years ago, 5% and 10% carbaryl powder agents were mainstay of flea control on both dogs and cats. Couple days later owner called in to update the case. She states that Apollo is back to normal and doing great. The owner just monitored him at home and his stool is firm now.
Mineure
The information contained in this report is based on self-reported statements provided to the registrant during telephone Interview(s). These self-reported descriptions of an incident have not been independently verified to be factually correct or complete descriptions of the incident. For that reason, information contained in this report does not and can not form the basis for a determination of whether the reported clinical effects are causally related to exposure to the product identified.